Nilaya Varma, Group CEO and Co-founder, Primus Partners, shared his view on the changing landscape of the global generics industry. He highlighted that India's pharmaceutical exports have grown significantly—from $15 billion in 2013–14 to nearly $28 billion over the last decade—driven by the country’s 750+ USFDA-approved facilities and expanding expertise in complex generics and biosimilars. With major global players scaling down operations, Indian companies are well-placed to seize the $180 billion loss-of-exclusivity opportunity